Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 62.

https://doi.org/10.1182/blood-2021-146932

Published: 2021

Journal Articles

Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM

Vaidie Julien, MD, Delphine Rea, MD, Sylvain Thepot, MD, Le Pluart Bruno, MD, Nathalie Gachard, PhD, Stéphanie Struski, MD, Lydia Roy, MD, Cecile Bally, MD, Jo Caers, MD PhD, Franck E Nicolini, MD PhD, Bruno Cassinat, PharmD, PhD, Eric Lippert, MD PhD, Laurence Legros, MD PhD, Raphael Itzykson, MD PhD

Blood (2019) 134 (Supplement_1): 2954.

https://doi.org/10.1182/blood-2019-127254

Published: 2019

Journal Articles

Outcome of NPM1 Mutated Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMAs): A Report on 71 Cases

Pedro H Prata, MD, Cecile Bally, Thomas Prebet, MD PhD, Christian Recher, MD PhD, Geoffroy Venton, Xavier Thomas, MD, Emmanuel Raffoux, MD, Arnaud Pigneux, MD PhD, Thomas Cluzeau, MDPhD, Judith Desoutter, Julie Gay, Claude Preudhomme, PharmD, PhD, Pierre Fenaux, MD PhD, Lionel Ades, MD PhD

Blood (2017) 130 (Supplement 1): 1335.

https://doi.org/10.1182/blood.V130.Suppl_1.1335.1335

Published: 2017

Journal Articles

Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia

Cecile Bally, Jacqueline Lehmann-Che, Bruno Cassinat, PharmD, PhD, Lionel Ades, MD PhD, Eric Letouze, Pierre Hirsch, Marie-Joelle Mozziconacci, Sophie Raynaud, MD, Eric Delabesse, PharmD, PhD, Madalina Uzunov, MD, Mathilde Hunault, MD PhD, Eric Lippert, PhD, Hélène Lapillonne, MD PhD, Christophe Ferrand, PhD, Carine Gervais, MD, Nathalie Gachard, PhD, Agnès Guerci, MD PhD, Pierre Fenaux, MD PhD, Hugues de The, MD PhD

Blood (2016) 128 (22): 2892.

https://doi.org/10.1182/blood.V128.22.2892.2892

Published: 2016

Journal Articles

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

Blood (2016) 128 (22): 347.

https://doi.org/10.1182/blood.V128.22.347.347

Published: 2016

Journal Articles

Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases

Philippe Attias, Aline Renneville, MD, Xavier Thomas, MD PhD, Cecile Bally, Sandrine Hayette, Hassan Farhat, MD, Virginie Eclache, MD, Alice Marceau, Bruno Cassinat, PharmD, PhD, Jean Feuillard, MD PhD Pr, Christine Terré, PharmD, PhD, Eric Delabesse, PharmD, PhD, Sophie Park, MD PhD, Julie Lejeune, Sylvie Chevret, MD PhD, Lionel Ades, MD PhD, Claude Preudhomme, MD PhD, Pierre Fenaux, MD PhD

Blood (2016) 128 (22): 2861.

https://doi.org/10.1182/blood.V128.22.2861.2861

Published: 2016

Journal Articles

Detection of TP53 Mutations in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). a Comparison Between a Functional Method (FASAY) and Next Generation Sequencing (NGS)

Cécile Bally, Aline Renneville, Lionel Adès, MD PhD, Claude Preudhomme, Hugues de Thé, MD PhD, Pierre Fenaux, MD PhD, Jacqueline Lehmann-Che, PharmD, PhD

Blood (2014) 124 (21): 3266.

https://doi.org/10.1182/blood.V124.21.3266.3266

Published: 2014

Journal Articles

Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine

Cecile Bally, Lionel Ades, MD, PhD, Aline Renneville, MD, Claude Preudhomme, Marie-Joelle Mozziconacci, MD, PhD, Hugues de The, MD, PhD, Jacqueline Lehmann-Che, Pierre Fenaux, MD, PhD

Blood (2012) 120 (21): 1706.

https://doi.org/10.1182/blood.V120.21.1706.1706

Published: 2012

Journal Articles

Azacitidine Treatment for Lenalidomide (LEN)-Resistant Myelodysplastic Syndrome (MDS) with Del 5q

Rami S. Komrokji, MD, Cecile Bally, Raphael Itzykson, Sylvain Thepot, Eric Padron, MD, Najla H Al Ali, Jeffrey E Lancet, MD, Alan F. List, MD, Pierre Fenaux, MD, PhD, Lionel Ades, MD, PhD

Blood (2012) 120 (21): 3833.

https://doi.org/10.1182/blood.V120.21.3833.3833

Published: 2012

Journal Articles

Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.

Cecile Bally, Lionel Ades, MD, PhD, Aline Renneville, MD, Sophie Raynaud, Virginie Eclache, MD, Thomas Cluzeau, MD, PhD, Mathilde Hunault-Berger, MD, PhD, Aspasia Stamatoullas, MD, Christian Bastard, MD, Michaela Fontenay, MD, PhD, Marie-Joelle Mozziconacci, MD, PhD, Claude Preudhomme, Hugues de The, MD, PhD, Pierre Fenaux, MD, PhD, Jacqueline Lehmann-Che, PharmD, PhD

Blood (2012) 120 (21): 2809.

https://doi.org/10.1182/blood.V120.21.2809.2809

Published: 2012

Journal Articles

Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q

Cecile Bally, Raphael Itzykson, MD, Berangere Gruson, MD, Dreyfus Francois, Virginie Siguret, Anne-Laure Taksin, Benoit de Renzis, Laurence Legros, Xavier Thomas, MD, PhD, Krimo Bouabdallah, MD, Pascal Chaibi, MD, Charikleia Kelaidi, Pierre Fenaux, MD, PhD, Lionel Ades

Blood (2011) 118 (21): 2786.

https://doi.org/10.1182/blood.V118.21.2786.2786

Published: 2011

Journal Articles

AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM)

Jehane Fadlallah, Cecile Bally, Bruno Quesnel, Norbert Vey, Francois Dreyfus, Pascal Turlure, Stephane de Botton, Caroline Dartigeas, Benoit de Renzis, Sylvain Thepot, Raphael Itzykson, Pierre Fenaux, MD, PhD, Lionel Ades

Blood (2010) 116 (21): 2911.

https://doi.org/10.1182/blood.V116.21.2911.2911

Published: 2010

Journal Articles

Outcome of APL In Young Children and Adolescents In Two Consecutive Trials of the European APL Group,

Cecile Bally, Jehane Fadlallah, Guy Leverger, Yves Bertrand, Alain Robert, Andre Baruchel, Agnes Guerci, Christian Recher, Emmanuel Raffoux, Xavier Thomas, Thierry Leblanc, Norbert Vey, Herve Dombret, Miguel Sanz, Pierre Fenaux, Lionel Ades

Blood (2010) 116 (21): 507.

https://doi.org/10.1182/blood.V116.21.507.507

Published: 2010

NARROW

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Current Treatments Do Not Improve the Prognosis of Patients with Atypical CML and Unclassified MDS/MPN. a Joint Report from Fi-LMC, FIM, Gfch and GFM

Outcome of NPM1 Mutated Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMAs): A Report on 71 Cases

Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases

Detection of TP53 Mutations in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). a Comparison Between a Functional Method (FASAY) and Next Generation Sequencing (NGS)

Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine

Azacitidine Treatment for Lenalidomide (LEN)-Resistant Myelodysplastic Syndrome (MDS) with Del 5q

Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.

Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q

AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM)

Outcome of APL In Young Children and Adolescents In Two Consecutive Trials of the European APL Group,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only